Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: VRTX stock price vs CNMD: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at CNMD's multiple
Needs CNMD P/E.
Implied fair value · at VRTX's multiple
Needs VRTX P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Eight period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
VERTEX PHARMACEUTICALS INC / MA · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
CONMED CORPORATION · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
AMGEN INC
VRTX vs AMGN
Gilead Sciences, Inc.
VRTX vs GILD
BIOGEN INC.
VRTX vs BIIB
Moderna, Inc.
VRTX vs MRNA
Illumina, Inc.
VRTX vs ILMN
STRYKER CORP
VRTX vs SYK
ZIMMER BIOMET HOLDINGS, INC.
VRTX vs ZBH
INTEGRA LIFESCIENCES HOLDINGS CORP
VRTX vs IART
BAXTER INTERNATIONAL INC
VRTX vs BAX
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe VRTX can sustain its high margins and ROIC while continuing mid-single to high-single-digit growth, then hold or accumulate on weakness because the premium valuation is supported by superior profitability and a much stronger balance sheet relative to CNMD.
On a P/E basis, VRTX is priced almost exactly at the implied value, with current price of $477.10 versus implied price of $469.75, implying just -1.5% downside. However, relative to CNMD, VRTX commands a much higher multiple across revenue and EBITDA, reflecting a quality premium rather than a clear mispricing.
Supporting Metrics
